Veradermics, Inc - 8-K Filing
Veradermics reports positive topline 12-month data from Phase 2/3 Study '302' for VDPHL01 in male pattern hair loss. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Veradermics reports positive topline 12-month data from Phase 2/3 Study '302' for VDPHL01 in male pattern hair loss. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)